Global health aid agency Unitaid has written to Johnson & Johnson’s CEO Joaquin Duato, urging “immediate action” to expand access to the company’s tuberculosis drug bedaquiline, which is protected by patents hindering generic alternatives.
https://www.pharmalive.com/wp-content/uploads/2023/09/JnJ-Brussels.jpg412789Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-09-29 06:41:232023-09-29 10:12:01Aid agency urges Johnson & Johnson to improve access to tuberculosis drug
